| 2. 截至发稿，德国DAX指数涨0.09%，英国富时100指数跌0.22%，法国CAC40指数涨0.31%，欧洲斯托克50指数涨0.18%。 | | --- | | 3. 截至发稿，WTI原油涨0.42%，报64.63美元/桶。布伦特原油涨0.52%，报69.40美元/桶。 | 市场消息 市场抢跑"降息行情"：零售销售数据公布前，美债收益率持续走低。对于周二将公布的数据，经济学家预测，美国12月份零售销售额增速预计将从此前的 0.6%放缓至0.4%，而去年第四季度的就业成本指数预计将保持在0.8%的稳定水平。这些经济数据和随后的美联储官员的讲话可能会进一步强化进一步降息 的理由。美国10年期国债收益率下跌2个基点至4.18%，接近1月中旬以来的最低水平;而对政策更为敏感的美国2年期国债收益率下跌1个基点，呈现所谓 的"牛市趋平(bull-flattening,长端收益率比短端下得更快)"走势。货币市场目前预计美联储今年降息3次(每次降息25个基点)的概率约为25%，而一周前市场预 期降息2次。 盘前市场动向 1. 2月10日(周二)美股盘前，美股三大股指期货齐涨。截至发稿，道指期货涨0.06%，标普500 ...

Core Insights - Hong Kong's capital market showed remarkable performance in 2025, with total fundraising reaching $103 billion, a year-on-year increase of 164% [1][3] - The initial public offering (IPO) fundraising amounted to $37.4 billion, up 231% year-on-year, while post-listing refinancing reached $66 billion, a 136% increase [1][3] Group 1: Market Performance - Hong Kong regained its position as the global leader in new stock fundraising by the end of 2025, with 119 new listings raising a total of $37.4 billion, surpassing the total from the previous three years [3] - The average daily trading volume in the secondary market increased by 89.5% year-on-year, indicating high trading activity [1] Group 2: New Listings and Performance - New stocks with fundraising of $100 million or more saw an average first-day price increase of 23.8%, with an average one-month increase of 30.7%, marking the best performance in nearly 20 years [5] - Notable transactions included 20 large deals exceeding $1 billion, including the largest placement in the global automotive sector and the second-largest convertible bond deal in the tech sector [5] Group 3: Investor Participation - The investor base in Hong Kong's primary and secondary markets has become increasingly diverse, including global institutional investors and retail investors from mainland China [9] - Institutional investors accounted for a significant portion of the top 20 most active cornerstone investors in Hong Kong's equity capital market [9] Group 4: Industry Diversity - Hong Kong maintained its status as a diversified fundraising center, ranking among the top globally in various industry fundraising scales [11] - In the industrial and new energy sectors, Hong Kong ranked first globally in new stock fundraising at $14.3 billion and second in equity capital market issuance at $24.7 billion [13] Group 5: Future Trends - The capital market in Hong Kong started strong in 2026, with equity capital market issuance reaching $15.8 billion by January 30, six times the amount from the same period in 2025 [16] - The artificial intelligence sector is expected to play a significant role in IPO activities, contributing to a vibrant ecosystem for innovative companies [16]

Market Overview - A-shares experienced narrow fluctuations, with the Sci-Tech Innovation Board showing strong performance, particularly in AI applications and computing chips [1] - The Hong Kong stock market saw a significant rebound in the pharmaceutical sector, with the Hong Kong Innovation Drug ETF (520880) reaching a peak increase of 3.86% and closing up 2.9% [3][5] ETF Performance - The Hong Kong Innovation Drug ETF (520880) recorded a trading volume of 5.9 billion, while the Hong Kong Medical ETF (159137) rose by 2.1%, marking its sixth consecutive day of gains [2][3] - The Sci-Tech Artificial Intelligence ETF (589520) increased by 1.81%, with a peak rise of over 2.4% during the trading session [8] Industry Insights - The Chinese innovative drug sector is experiencing a dual breakthrough in internationalization and commercialization, with over 70% of innovative drug companies reporting positive revenue growth [6][7] - Significant collaborations in the innovative drug space include a strategic partnership between Innovent Biologics and Eli Lilly, valued at up to $8.85 billion, and a $18.5 billion collaboration between CSPC Pharmaceutical and AstraZeneca [6] AI and Technology Developments - ByteDance's recent launches, including the Seedance 2.0 video generation model and Seedream 5.0 image generation model, have generated significant interest in the AI sector [11] - The Sci-Tech Artificial Intelligence ETF (589520) has a substantial exposure to ByteDance, with a weight of 29.42% in its index [11][13] Semiconductor and Chip Industry - The semiconductor equipment industry is experiencing an upward trend, with projected sales growth of 26% in 2026, reaching $791.7 billion [17] - The Sci-Tech Chip ETF (589190) is positioned to benefit from the ongoing "super cycle" in the semiconductor industry, with a focus on domestic production and expansion [15][17] Investment Strategy - Analysts suggest that the current market conditions present a favorable opportunity for investment in innovative drugs and AI sectors, with a recommendation to focus on ETFs that track these industries [7][19] - The Sci-Tech Chip ETF has shown a strong annualized return of 17.93%, outperforming other semiconductor indices [19][20]

Core Viewpoint - Fuyuan Pharmaceutical's subsidiary has received approval for the production of a new oral solution, indicating a positive development in its product pipeline and potential revenue growth [2]. Group 1: Company Developments - Fuyuan Pharmaceutical announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the oral solution of Ambroxol Hydrochloride (specification: 200ml: 160mg) [2]. - The approval of this drug is a significant milestone for the company, as it expands its product offerings in the pharmaceutical market [2]. Group 2: Industry Implications - The approval of new pharmaceutical products is crucial for companies in the industry, as it can lead to increased market share and revenue [2]. - This development reflects the ongoing regulatory support for new drug approvals, which is essential for innovation and competition within the pharmaceutical sector [2].

Core Viewpoint - The collaboration between Pianzaihuang and Shanghai Lidao Pharmaceutical Technology Co., Ltd. focuses on the development of the innovative drug PZH2107 for the treatment of fibromyalgia, which has entered the Phase II clinical trial stage [1][2]. Group 1: Company Developments - Pianzaihuang announced the completion of the first subject enrollment for the Phase II clinical trial of PZH2107, which is designed as a randomized, double-blind, placebo-controlled, multi-center study [1]. - The drug PZH2107 is available in two dosages: 5mg and 20mg, specifically targeting fibromyalgia treatment [1]. - The clinical trial protocol has received approval from the ethics committee of the Beijing Union Medical College Hospital, with the first subject enrolled on February 8, 2026 [1]. Group 2: Industry Insights - Fibromyalgia is a common chronic pain syndrome with a prevalence rate of 2%-4% in the general population, often accompanied by fatigue, sleep, and emotional disorders [2]. - The fibromyalgia treatment market is projected to reach $4.69 billion by 2035, according to ResearchNester [2]. - Current first-line treatments, such as pregabalin, duloxetine, and milnacipran, only partially alleviate symptoms and are associated with significant side effects, indicating an unmet clinical need for more effective treatment options [2].

证券日报网讯 2月10日，新华制药在互动平台回答投资者提问时表示，公司始终致力于心无旁骛发展医 药主业，努力为各利益相关方创造更多回报。 （文章来源：证券日报） ...

Group 1 - Dow futures rose by 0.09%, S&P 500 futures increased by 0.10%, and Nasdaq futures gained 0.07% [1] - Philips reported Q4 2025 earnings with a 1% year-over-year sales increase to €5.1 billion and an adjusted EBITA of €770 million, exceeding market expectations, leading to a 6.89% stock increase [2] - Cisco launched a new AI network chip, "Silicon One G300," expected to enhance AI computing task speeds by 28%, utilizing TSMC's 3nm process technology [2] Group 2 - Alphabet, Google's parent company, initiated its first issuance of Swiss franc bonds and British pound bonds, with maturities ranging from 3 to 100 years [2] - TSMC reported January sales of NT$401.26 billion, a 36.8% year-over-year increase and a 19.8% month-over-month rise, leading to a 3.09% stock increase [2] - BP's Q4 earnings showed a benchmark replacement cost profit of $1.54 billion, aligning with analyst expectations, but the full-year net profit of $7.49 billion fell short of the $7.58 billion forecast, resulting in a 4.9% stock decline [2] Group 3 - AstraZeneca's 2025 total revenue reached $58.739 billion, an 8% year-over-year increase, with growth in biopharmaceuticals, oncology, and rare diseases, and plans for significant investment in China [3] - AppLovin's stock rose by 3.5% after a short-seller retracted allegations against a major shareholder, ensuring the protection of legal rights [3] Group 4 - Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics to gain CAR-T therapy technology, aiming to produce cells in vivo rather than in the lab [4] Group 5 - Optical communication stocks saw a pre-market surge, with Redo Technology up over 17%, Astera Labs rising over 5%, and Corning increasing by over 1% [5]

长风药业(02652)公布，2026年2月10日耗资约37.05万港元回购1.05万股股份。 ...

阿斯利康：2025财年宣布的总股息提高3%，至每股3.20美元。 来源：滚动播报 ...

业绩方面，2024年以来，华润医药归母净利润持续下滑。2024年，华润医药实现营收约2577亿元，同比 增长5.3%；归母净利润约33.51亿元，同比下滑13.06%。2025年上半年，实现营收约1319亿元，同比增 长2.54%；同期归母净利润约20.77亿元，同比下滑20.30%。 据企查查，截至2026年2月10日，华润医药及其子公司华润医药投资共持有天麦生物科技23.75%股权。 其中，华润医药投资直接持股20%，系天麦生物科技的第一大股东。 此次华润医药出售其持有的天麦生物科技大部分股份，业内认为，一方面，是华润系聚焦主业剥离非核 心资产之举，另一方面，天麦生物科技重点布局的口服胰岛素上市失败也是影响因素之一。 2025年12月29日，国家药监局网站显示，天麦生物科技参股公司合肥天汇生物科技有限公司申请的重组 人胰岛素肠溶胶囊（ORMD-0801）收到药品通知件，即未能获批上市。ORMD-0801是重组人胰岛素肠 溶胶囊，口服给药，用于需要用胰岛素的糖尿病患者的治疗。该品种最初由Oramed Pharmaceutical Inc. 研发，从2015年底开始，天麦生物与Oramed Pharmaceu ...